Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors and Everolimus for treating advanced renal cell cancer
Withdrawn

Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors and Everolimus for treating advanced renal cell cancer

Condition

Cancer

Kidney

2 January 2024

Published on 04 Jan 2022
Last Updated on 02 Jan 2024

Tyrosine Kinase inhibitors, Immune Checkpoint inhibitors and Everolimus for treating advanced renal cell cancer Guidance is outdated and has been withdrawn on 31 Aug 2022.
Please refer to the updated recommendations on Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions here.

The Plain English Summary (PES) has been updated on 31 August 2022.

PES Treatments for advanced renal cell carcinoma (Updated 2 Jan 2024) [PDF, 226 KB]

Tyrosine Kinase inhibitors, Immune checkpoint inhibitors and everolimus for treating advanced RCC (Withdrawn 31 Aug 2022) [PDF, 111 KB]

Back to top